SecBot SecBot
SECBOTREPLAY Home › Report › ORKA

ORKA · Oruka Therapeutics, Inc

Oruka Therapeutics, Inc. · DEFA14A filed Apr 17, 2026 at 16:15 ET

At the news

NEUTRALIMPACT 3/10

DEFA14A filed Apr 17, 2026 at 16:15 ET

Oruka Therapeutics, Inc. (ORKA) has filed a definitive proxy statement (DEFA14A) for its 2026 Annual Meeting, scheduled for June 2, 2026. The meeting will address the election of two Class II directors, the ratification of PricewaterhouseCoopers LLP as the independent auditor, and the advisory approval of executive compensation. This is a routine annual shareholder meeting with no activist involvement or contentious issues.

  • The filing is a routine annual proxy statement for the 2026 shareholder meeting.
  • Three proposals are on the agenda: election of two Class II directors (Lawrence Klein and Chris Martin), ratification of the independent auditor, and advisory approval of executive compensation.
  • The meeting will be held virtually on June 2, 2026.
  • The filing was made by the registrant (Oruka Therapeutics, Inc.), indicating it is a standard management proposal.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access